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ABSTRACT 
End-of-life planning promotes patient autonomy by allowing individual patients to inform and direct care givers and 
healthcare proxies on their desired level of end-of-life care, where the patient prefers to pass away (whether at home or in 
a hospital setting), and the methods and levels of pain management that the patient deems desirable.  Given that, it is 
counter-intuitive that a significant majority of American's fail to execute, or fail to properly execute, advance directives.  
The author’s efforts focus on what can be done to improve, generally, end-of-life care.  To that end, the authors conclude 
that improvements in end-of-life care must be achieved at three levels: the individual level, the healthcare provider level, 
and at the government level.  On the individual level, patients must assume greater accountability for their own end-of-life 
care.  That entails making one's wishes for end-of-life care known to family members and healthcare providers.  On the 
healthcare provider level, improved patient communication and improved delivery of palliative-oriented care are first 
order initiatives. Finally, the government can play a significant role in improving end-of-life care by collecting better 
healthcare utilization and cost data on end-of-life experiences, expanding benefits for palliative care services, and 
promoting the use of advance directives through legislative efforts that include patient education measures. 
Florida Public Health Review, 2010; 7, 50-63. 
 
Background 
Perhaps at no point in this country’s recent 
history has a debate fueled emotions within the halls 
of Congress, and within the citizenry, more than 
healthcare reform. Much of the debate during the 
2009 healthcare reform effort, arguably President 
Barack Obama's biggest domestic policy initiative 
during his first year in office, has been rife with 
hyperbole; politicians have charged that reform of the 
American healthcare system will result in the creation 
of “death panels” that will “pull the plug on 
grandma” or otherwise coerce people to “die quickly” 
(Palin, 2009; Grayson. 2009). Consequently, end-of-
life considerations, mired with the complexities of 
patient autonomy, costs, and ethics, have been highly 
visible in the current healthcare reform debate. 
As a result of advancements in medicine and 
medical technology, individuals in the United States 
are living longer lives. Although these advances 
continue to increase life expectancy, attention to the 
quality of life and to the inevitable experience of 
dying, has not kept pace (Grady, 1999). With 
increasing life expectancies come increasing 
healthcare costs. To that end, there are three central 
concerns regarding end-of-life healthcare policy 
reform. Those are: (1) the use of advance directives 
and other measures that serve to increase patient 
autonomy; (2) the benefits of hospice care to improve 
the quality of care received at end-of life and avoid 
unnecessary costs associated with futile medical 
treatments at end-of-life; and, (3) the use of pain 
management at end-of-life and the delicate balance 
between patient autonomy and ethical medical 
treatment that must be achieved in connection 
therewith (Werth & Blevens, 2002). 
At the outset, it is important to establish the 
parameters of what constitutes end-of-life.  For 
purposes hereof, the National Institutes of Health 
definition is adopted. The term end-of-life can take 
on various meanings, and none are definitive.  
According to The National Institutes of Health, there 
are two constituent parts to end-of-life. The first is 
the presence of one or more chronic diseases, 
symptoms, or functional impairments that may persist 
or fluctuate.  The second is the presence of symptoms 
or impairments resulting from an underlying, 
irreversible disease, requiring formal (paid, 
professional) or informal (unpaid, unskilled) care, 
and can lead to death (Heitkemper, Bruner, et al., 
2004). End-of-life can also be defined by advanced 
age. However, with advanced age there are generally 
indicia of “debility, dementia, and protracted chronic 
and terminal illnesses”  (Hardwig, 2009). 
Individuals at end-of-life may face legal 
incapacity and rendering them incapable of 
expressing their wishes, with regard to end-of-life 
healthcare. This very point was evidenced in the Terri 
Schiavo case. Recall that Ms. Schiavo was in a 
persistent vegetative state and a fierce legal battle 
ensued between her parents and husband regarding 
who had the right, if anyone, to order her life support 
withdrawn. That legal battle played out in the 
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national news media in early 2005. The case 
ultimately ended with her various life support 
treatments being removed, and Ms. Schiavo passing 
away shortly thereafter. The case offered a valuable 
lesson in advance directives, and their vital 
importance within society. 
The majority of Americans fail to adequately 
plan for end-of-life.  As a result, many are ill-
prepared for end-of life and/or otherwise uneducated 
about available end-of-life planning tools. On the 
individual level, the risk of failing to plan for end-of-
life is the possibility of being unable, because of legal 
or physical incapacity, to relay one’s desired end-of-
life healthcare wishes. On the societal level, the 
implications of failing to adequately plan for end-of-
life can result in legal battles regarding healthcare 
decisions, and needless escalation of healthcare costs.  
“We do not have a [end-of-life] game plan as a 
society” (Gari, 2009). This proposition is a risky one. 
Though a controversial issue that touches upon 
medicine, law, ethics, religion, politics, common 
sense, and extremism, giving a patient the right to 
determine the manner in which he or she handles 
end-of-life (including the right to die) is a powerful 
directive that individuals and their families feel 
should be within their control (Haras, 2008; Caplan, 
McCartney, & Sisti, 2007). Further to that 
commonly-held sentiment, it becomes apparent that 
understanding and using advance planning directives 
is essential. Advance directives, including living 
wills, healthcare proxies, do-not-resuscitate (DNR) 
orders, and healthcare powers of attorney, are legal 
documents governed by state law that express an 
individual's choice of surrogate healthcare decision-
maker and/or an individual's treatment preferences in 
the event of incapacity  (Kohn & Blumenthal, 2008; 
Darr, 1999). Even though the importance of advance 
directives is high, it is estimated that the use of 
advance directives is relatively low—between 16% 
and 27% (Cohen-Mansfield & Lipson, 2008; Ho, 
Thiel, Rubin, & Singer, 2000; Rosnick & Reynolds, 
2003; Wallace, Weiner, Pekmezaris, Almendral, 
Cosiquien, Auerbach, & Wolf-Klein, 2007). Most 
significantly, for purposes of the instant discussion, 
advance directives generally provide instruction as to 
whether the maker wishes to receive or decline 
artificial life-sustaining treatments at end-of-life. 
Advance directives may serve a financial 
purpose, aiding in healthcare cost containment. This 
is a commonsense conclusion. If an individual is 
willing to forgo costly measures to artificially sustain 
life and/or other heroic end-of-life treatment options, 
we assume that there will be a resulting net reduction 
in the cost of end-of-life treatment provided to that 
individual (Nishimura, 2007). There is research that 
substantiates this assumption, while other research 
has been inconclusive (Mezey & Ramsey, 1994). 
Irrespective of the cost containment issue, it is 
important not to lose sight of the reason advance 
directive laws exist.  That is, to carry out the 
intentions and wishes of the person making the 
advance directive in the event of his or her 
incapacity. 
 
Patient Autonomy: Legislative Attempts at End-
of-Life Planning Mandates 
America's Affordable Health Choices Act 
 In any end-of-life discussion, a complex set of 
policy issues, economic issues, and legal issues is 
expected to emerge.  Weighty ethical concerns are 
adjunctive thereto.  Public debate of end-of-life 
issues abounded following the introduction, in mid-
July 2009, of the America's Affordable Health 
Choice Act (H.R. 3200). H.R. 3200 was politicized 
for the reason that the proposed legislation contains a 
provision for advance care planning consultations in 
Section 1233 thereof (H.R. 3200 § 1233). Such 
advance care consultations—proposed to take place 
on a voluntary basis every five years between a 
patient, namely, a Medicare or Medicaid recipient, 
and his or her healthcare practitioner—include 
explanation, by the healthcare practitioner, of 
advance directives and the continuum of end-of-life 
services, including palliative care and hospice care.  
One of the more controversial provisions within H.R. 
3200 § 1233 includes providing patients with “an 
explanation of orders regarding life sustaining 
treatment or similar orders … [and] the reasons why 
the development of such an order is beneficial to the 
individual and the individual's family.” Impliedly 
contained within H.R. 3200 § 1233 is the dictum that 
executing an advance directive  is beneficial for the 
reason that it ensures that the individual's wishes 
regarding end-of-life care will be carried out, in the 
event that the individual becomes incapacitated and 
unable to make his or her own healthcare decisions. 
H.R. 3200, the proposed legislation responsible 
for the timeliness of this discussion, comprises a 
significant piece of proposed legislation in the 2009 
healthcare reform initiative, but it is by no means the 
only proposed legislation germane to that effort.  
H.R. 3200 is the product of three U.S. House 
Committees, namely, the House Energy and 
Commerce Committee; the House Ways and Means 
Committee; and the House Education and Labor 
Committee.  Collectively, these committees, with 
regard to H.R. 3200, are sometimes called the “Tri-
Committee.” There are additionally two pieces of 
proposed legislation relating to the 2009 healthcare 
reform initiative introduced in the U.S. Senate.  
Those are America's Healthy Future Act of 2009 (S. 
1796) introduced in the Senate Finance Committee 
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and the Affordable Health Choices Act (S. 1679).  
Significantly, neither Senate bill includes language 
similar to H.R. 3200 § 1233 or otherwise provides for 
advance care planning consultations. 
H.R. 3200 § 1233, has been attacked on the basis 
that it is, according to its opponents, intended to 
dissuade certain persons from consuming certain end-
of-life healthcare treatments–charging, essentially, 
that there is potential for abusive and/or disparate 
application. In particular, H.R. 3200 § 1233 is limited 
to Medicare and/or Medicaid recipients and, 
accordingly, it is those persons who would receive 
the voluntary (or, voluntary but for the “white coat” 
influence) advance care planning consultations 
provided for therein. It is proposed that those 
consultations occur at five-year intervals or “more 
frequently … if there is a significant change in the 
health condition of the individual, including 
diagnosis of a chronic, progressive, life-limiting 
disease, a life-threatening or terminal diagnosis, or 
upon admission to a skilled nursing facility” (H.R. 
3200 § 1233). There can be little argument that 
aforementioned group (Medicare and/or Medicaid 
recipients) is comprised largely of the elderly, the 
terminally-ill, or other groups which may be at or 
near the end-of-life stage.  By reimbursing physicians 
for time spent counseling patients who experience “a 
significant change in … health condition” a straight-
faced argument can be made that § 1233 promotes 
the use of advance directives as a means of cost 
containment and/or healthcare rationing. Further, that 
cost containment or healthcare rationing would come 
at the cost of disproportionately providing less 
available healthcare services and measures, to 
Medicare and/or Medicaid recipients. This, though, 
may be an incurable inequity inasmuch as some 
research suggests that physicians treating patients 
whose care is covered by government-funded 
insurance (namely, Medicare and Medicaid) are more 
likely to issue a DNR order, or otherwise forgo 
heroic end-of-life treatment options, than they are for 
patients covered by private insurance (Nordquist, 
2006). 
Proponents of H.R. 3200 § 1233 advocate the 
position that advance care planning consultations 
necessarily involve only cognitive and legally 
competent persons.  Furthermore, in connection with 
providing an advance care planning consultation 
under § 1233, a healthcare practitioner is required to 
advise the patient of the substantial legal safeguards 
available. This would further protect the individual 
against the risk of an appointed surrogate healthcare 
decision-maker terminating life-sustaining measures 
based on the surrogate's judgment, morals and/or 
values  (H.R. 3200). Those favoring legislation which 
encourages advance care planning argue that such 
“measure[s] would not only help people make the 
best decisions for themselves, but also ensure that 
their wishes are followed.  To suggest otherwise is a 
gross, even cruel, distortion, especially for a family 
that has been forced to make the difficult decisions 
on care for loved ones approaching the end of their 
lives” (Blumenauer, 2009). The cost containment 
argument cannot be ignored here. Proponents of 
legislative efforts to encourage the use of advance 
directives also maintain that the outcome will be  the 
alleviation of exorbitant federal spending on costs 
incurred, arguably, largely in connection with futile 
efforts to unnaturally extend the life of an individual 
(Schneider & Hall, 2009). 
Further substantive discussion of  by H.R. 3200 
§ 1233—which may be somewhat cumulative in light 
of the Patient Self-Determination Act, infra—is not 
ripe as it has not as of the time of this writing, and 
perhaps may not, mature into enacted federal 
legislation.  However, the proposed legislation did, as 
previously mentioned, serve to bring the end-of-life 
planning issue to the forefront of the American 
conscious.  It also served to bring to light the 
question of whether federal legislative efforts can 
increase the use of end-of-life planning instruments 
such as advance directives.  Analysis of other enacted 
federal and state legislation is both germane and 
instructive in the end-of-life planning discussion at 
this juncture. In particular, the Patient Self-
Determination Act is examined herein relative 
encouraging end-of-life planning in furtherance of 
patient autonomy.  Additionally, the Oregon Death 
with Dignity Act and the Washington Death with 
Dignity Act, which authorize physician-assisted 
suicide in limited circumstances in those states, are 
examined relative to their policy implications relative 
to patient autonomy at end-of-life.  The concomitant 
economic effects of those legislative initiatives are 
also addressed. 
Patient Self-Determination Act 
The Patient Self-Determination Act (42. U.S.C. 
§§ 1381, et seq.) (hereinafter the “PSDA”), enacted 
in 1991, made it a federally legislated requirement 
that individuals treated in institutions receiving 
Medicare and/or Medicaid reimbursements be asked 
about the presence or the absence of an executed 
advance directive regarding that individual's express 
wishes for potential end-of-life care (42 U.S.C. § 
1395). The legislative purpose behind the PSDA was 
to increase the use of advance directives regarding 
end-of-life treatment decisions (O'Rourke, 2000).  In 
relation to H.R. 3200 § 1233, the language of the 
PSDA is notably less value-laden. The specific 
language of the PSDA provides that “each hospital 
nursing facility, provider of home healthcare or 
personal care services, hospice program, or health 
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maintenance organization…receiving funds under 
[Medicaid and/or Medicare] shall…provide written 
information…concerning an individual's right under 
State law (whether statutory or recognized by the 
court of the State) to make decisions concerning such 
medical care, including the right to accept or refuse 
medical or surgical treatment and the right to 
formulate advance directives…[and] to document in 
the individual's medical record whether or not the 
individual has executed an advance directive”  (42 
U.S.C. § 1395 cc (a)). The PSDA does not require the 
healthcare provider to determine the legal sufficiency 
of the advance directive or obtain a copy thereof 
(Mezey & Ramsey, 1994). By presenting an 
individual's right to execute an advance directive as 
an individual choice to accept or refuse certain life-
sustaining treatments, the PSDA is significantly more 
value-neutral than H.R. 3200 § 1233.  Also, under the 
PSDA, a covered institution may not make the 
provision of care conditional upon whether the 
individual has or has not executed an advance 
directive, to do so is considered discriminatory under 
the Act (Mezey & Ramsey, 1994; 42 U.S.C. § 1395cc 
(a)(2)(C)). H.R. 3200 provides reimbursements to 
physicians for time spent conducting advance care 
planning consultations held, in part, for the purpose 
of explaining to the individual “the reasons why the 
development of such an order is beneficial to the 
individual and the individual's family” (H.R. 3200 § 
1233). There is no explanation in H.R. 3200 as to 
how the proposed legislation presumes advance 
directives to be beneficial. One view is that they are 
beneficial for the reason that they are designed to 
instruct family and/or healthcare provider, on how an 
individual may desire to carry out end-of-life 
treatment. A more cynical view is that forgoing 
certain end-of-life treatments result in less federal 
healthcare spending. 
One major difference between H.R. 3200 § 1233 
and the PSDA regarding advance directives is that 
H.R. 3200 § 1233 proposes to educate individuals on 
advance directives. There is not a similar education 
component in the PSDA. Accordingly, to the extent 
that later federal legislation may provide for patient 
education regarding advance directives, the same 
would not be wholly cumulative in light of the 
PSDA. It is significant to note that research suggests 
that advance care planning education (in the nature of 
that proposed by H.R. 3200 § 1233) may increase the 
rate at which advance directives are executed, but 
that the resulting executed advance directives may 
fall short of the legal requirements set forth by state 
law to make them sufficient, valid and/or enforceable  
(Ho, et al., 2000; Aroskar, Moldow, & Good, 2004).  
Therefore, a critical failure of any law enacted for the 
purpose of increasing the use of advance directives, 
that does not require a determination as to whether or 
not an individual has a valid and legally enforceable 
advance directive, is that a significant number of 
individuals may believe that they have an advance 
directive, and may report that fact to their healthcare 
provider, when, in fact, they have executed a 
document which cannot later be given effect.  Neither 
the PSDA nor the proposed H.R. 3200 requires that 
the legal sufficiency of an individual's advance 
directive be determined. 
It is suggested that that legislative efforts can 
positively influence the rate at which individuals 
execute advance directives to express their wishes for 
end-of-life, which conforms to the legislative purpose 
of the PSDA. Accordingly, the ability of legislation 
to change patterns of end-of-life care consumption 
and the ability of legislation to promote the use of 
advance directives is a potent consideration.  To that 
end, it is suggested that further research is needed to 
determine whether narrowly tailored legislation, 
which includes a patient education component and a 
means for determining the legal sufficiency of 
advance directives, is likely to positively impact 
patient autonomy at end of life. 
The Right to Die 
The right to die may be the ultimate measure of 
patient autonomy. When considering various end-of-
life options for terminally ill patients, it must be 
considered whether physician-assisted suicide is a 
viable one. Oregon became the first state in the 
United States to permit physician-assisted suicide in 
1997. Eleven years later, Washington state, became 
the second (Campbell, 2008; Jecker, 2009). 
The Oregon Death with Dignity Act (Or. Rev. 
Stat. Ch. 127, hereinafter the “Oregon DWDA”) and 
the Washington State's Death with Dignity Act (Rev. 
Code of Wash. §§ 70.245.010, et seq., hereinafter the 
“Washington DWDA”) are measures of patient 
autonomy inasmuch as they provide a legal right for 
physician-assisted suicide in certain limited 
circumstances. The Oregon DWDA sets forth 
detailed requirements and procedures by which a 
mentally competent but terminally ill adult resident 
of Oregon may voluntarily “make a written request 
for medication for the purpose of ending his or her 
life in a dignified manner” (Or. Rev. Stat. 
§127.805(1)). The patient must be suffering from “an 
incurable and irreversible disease that has been 
medically confirmed and will, within reasonable 
medical judgment, produce death within six months”  
(Or. Rev. Stat. § 127.800(12)). The patient's written 
request must be signed and dated in the presence of at 
least two witnesses who attest that the patient is 
“competent and acting voluntarily” (Or. Rev. Stat. § 
127.810(1)). The Washington DWDA, modeled after 
the Oregon statute, contains substantially similar 
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limitations on its application.  The Oregon DWDA 
was enacted primarily to “expand patient control over 
end-of-life choices” (Campbell, 2008). Between 1998 
and 2008, 401 individuals ended their lives under the 
Oregon DWDA (Oregon Department of Human 
Services).  In 1998, 97% of those individuals died at 
home, whereas 98% had some form of hospice care.  
The primary reason, as stated by 95% of those 
terminally-ill individuals choosing to end their lives 
under the Oregon DWDA, was loss of autonomy.  
Accordingly, there appears to be a compelling policy 
argument in favor of laws such as the Oregon DWDA 
and the Washington DWDA in furtherance of patient 
autonomy. 
Prior to enactment of the Oregon DWDA, the 
state of the law regarding physician-assisted suicide 
was shaped by two United States Supreme Court 
decisions rendered in 1997.  In the first seminal case,  
Washington v. Glucksberg, 521 U.S. 702 (1997), the 
Supreme Court held that a Washington state law 
banning physician-assisted suicide was constitutional 
and, accordingly, an individual, even a terminally-ill 
individual, has no constitutionally protected right to 
die by means of intervention provided by a licensed 
medical physician (i.e., physician-assisted suicide). 
Specifically, the Supreme Court held that 
“[t]hroughout the Nation, Americans are engaged in 
an earnest and profound debate about the morality, 
legality, and practicality of physician-assisted 
suicide.  Our holding permits this debate to continue, 
as it should in a democratic society” Glucksberg, 521 
U.S. at 737. This holding suggests that states have the 
right to enact legislation permitting physician-
assisted suicide in limited instances. The second 
contemporaneously issued Supreme Court ruling, 
rendered in Vacco v. Quill, 521 U.S. 793 (1997) held, 
similarly, that a New York state law that banned 
physician-assisted suicide in that state was 
constitutional. The Vacco Court decided that states 
could ban physician-assisted suicide but it was silent 
as to whether a state could affirmatively authorize the 
same. 
Glucksberg and Vacco  seemingly opened the 
door for state legislation permitting physician-
assisted suicide in limited instances where the 
“proper balance between the interests of terminally 
ill, mentally competent individuals who seek to end 
their suffering and the State's interests in protecting 
those who might seek to end life mistakenly or under 
pressure” could be achieved (Glucksberg, 521 U.S. 
At 737). Nonetheless, the Oregon DWDA faced 
significant legal challenges following its enactment.  
Those challenges were based primarily on the federal 
Controlled Substances Act (21 U.S.C. §§ 801, et seq., 
hereinafter the CSA).  The CSA is a federal law that 
regulates the legal and illicit manufacture, 
distribution, and possession of controlled substances.   
Oregon physicians who sought to assist terminally-ill 
patients in ending their lives in conformity with the 
Oregon DWDA, were threatened with federal 
prosecution for violation of the CSA, by reason of a 
2001 interpretive rule issued by the U.S. Attorney 
General (John Ashcroft, at that time) which opined 
“assisting suicide is not a 'legitimate medical purpose' 
within the meaning of 21 C.F.R. § 1306.04 (2001), 
and that prescribing, dispensing, or administering 
federally controlled substances to assist suicide 
violates the CSA. Such conduct by a physician 
registered to dispense controlled substances may 
'render his registration...inconsistent with the public 
interest' and therefore subject to possible suspension 
or revocation under 21 U.S.C. § 824(a)(4).  This 
conclusion applies regardless of whether state law 
authorizes or permits such conduct by practitioners or 
others and regardless of the condition of the person 
whose suicide is assisted.” This interpretative rule 
came to be known as the Ashcroft Directive (Hilliard, 
2005). Accordingly, under the Ashcroft Directive, 
any physician who prescribed a lethal dose of a 
controlled substance to a terminally-ill patient would 
be subject to federal criminal prosecution. 
The United States Supreme Court ultimately 
resolved that the Attorney General was not 
authorized to issue an interpretive rule limiting the 
right of the State of Oregon to legislate medically 
appropriate uses of drugs not otherwise prohibited 
under the CSA—that matter is reserved to the states. 
Gonzales v. Oregon, 546 U.S. 243 (2006).  To that 
end, physician-assisted suicide in the limited manner 
provided by the Oregon DWDA is specifically 
sanctioned and similar legislation may be enacted by 
the various states. 
Whereas patient autonomy is a paramount 
concern at end-of-life, and in healthcare policy more 
generally, the matter of physician-assisted suicide is 
not appropriate for national policy.  The “challenging 
task of crafting appropriate procedures for 
safeguarding…liberty interests is entrusted to the 




It should come as no surprise that medical costs 
tend to increase with age, with the peak spending rate 
coming at the final stages of life. The Kaiser Family 
Foundation, a leader in health policy 
communications, conducted a study in 2006, 
highlighting the enormous increase in healthcare 
spending at end-of-life. The Kaiser Family 
Foundation study examined six age groups: newborn 
to age 5; age 5 through 17; age 18 through 24; age 25 
through 44; age 45 through 64; and 65 years of age 
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and older. The latter group, which is Medicare-
eligible and which accounts for 70% of all deaths in 
the United States annually, consumed, on average, 
$8,776 in federal healthcare dollars per person in 
2006 (Grady, 2009; Adamy, 2009). This figure is 
almost $4,000 more than the next highest spending 
age group: those between the ages of 25-44. The 
findings reported by the Kaiser Family Foundation 
support the argument that there is extraordinary 
spending in the final stages of life. The study also 
raises questions, with regard to whether Americans 
are being over-treated at end-of-life. The U.S. 
healthcare system offers multifarious treatment 
options during an individual's end-of-life period.  
However, many seeking care often go directly to the 
hospital, regardless of their signs or symptoms. This 
often drives up unnecessary costs and further 
increases pressure on curbing medical spending 
during end-of-life. Many are unaware of other end-
of-life care options that can provide an appropriate 
level of care, at a more modest cost. A survey 
conducted with the input of 2,515 Medicare patients 
found that 86% of those surveyed would rather spend 
the last days of their lives at home, rather than in a 
hospital. However, 80% of Americans die in 
institutions, mainly hospitals or nursing homes (Jaffe, 
2009). 
With Baby Boomers entering retirement age, 
Medicare, Medicaid, and Social Security spending 
are on the rise in the United States.  As of 2008 there 
were over 45.3 million Medicare beneficiaries 
(Overview Medicare Enrollment Reports, 2008) 
consuming $468 billion in healthcare services 
annually. This number amounts to 3.2% of the 
nation's total Gross Domestic Product (GDP), and 
that figure is projected to balloon to 11.4% over the 
next 70 years (Medicare Trustees Report & Trust 
Funds, 2009). By that estimate, Medicare spending 
will reach $931.9 billion by 2019—essentially 
doubling in the next 10 years (Jaffe, 2009).  Medicare 
spending is not distributed evenly over all 
beneficiaries.  From 1995-1999, 5% of Medicare 
beneficiaries accounted for some 47% of total 
Medicare spending (Lieberman, Lee, Anderson & 
Crippen, 2003).  As a result, end-of-life (and, more 
particularly, end-of-life healthcare spending) has 
become a hot button topic in American politics and 
policy. Because Medicare commands such a presence 
in the overall federal budget, cost containment in 
high spending areas has become a focal point.  So the 
following question arises:  How do we as a society 
cut costs, while at the same time, provide high quality 
healthcare to those in end-of-life scenarios? “In some 
[potentially end-of-life] cases hospital care is 
essential, especially for those experiencing trauma, 
cardiovascular, cerebrovascular, among other 
emergent events.” (Ortiz-Rios, 2009)  In other cases, 
however, individuals could receive the appropriate 
level of end-of-life care in the home, or in a hospice 
environment. When individuals choose to spend their 
final days in hospitals, they are choosing a costly 
option.  By way of example, an individual 65 years or 
older, suffering from pancreatic and/or liver cancer, 
seeking care in a Florida hospital, can expect to 
spend from $18,017 to $49,050 for a 6-day hospital 
stay (FloridaHealthFinder.gov, 2008).  The average 
of that range is $33,533. Many individuals turn to 
hospital care because that is the assumed choice.  
There is also a sense of comfort for patients knowing 
that they have a doctor or nurse in close proximity, 
no matter what time of the day it may be. 
Hospice care, though, offers a variety of end-of-
life treatment and care options for patients and their 
families, including in-home care, inpatient facilities 
(Hospice Houses), and around-the-clock nursing care.  
Hospice care is an ever-growing popular option for 
end-of-life care. In 2007, Hospice served 1.4 million 
patients, which is a 450,000-patient increase from 
2003 (NHPCO Facts and Figures, 2008). Hospice 
was also involved in 38.8% of all deaths occurring in 
the United States in the year of 2007 (NHPCO Facts 
and Figures, 2008).  It is a benefit that is covered by 
Medicare, and has been since 1982.  Significantly, 
hospice care is often less costly than hospital care.  In 
a typical hospice scenario, a family member serves as 
the primary care giver for the patient, with hospice 
healthcare providers being available 24 hours a day.  
An interdisciplinary team of healthcare providers 
works with family members to create an explicit care 
plan for the terminally ill individual.  Hospice often 
reduces cost while, at the same time, improves the 
quality of end-of-life care over that which would be 
received in a hospital or institutional setting.  A study 
conducted by Duke University researchers, 
concluded that hospice saves the Medicare program 
around $2,300 per beneficiary when the beneficiary 
expires in hospice care. The maximum cumulative 
savings noted by the study were as high as $7,000 
when beneficiaries with terminal illnesses used 
hospice for 58–103 days prior to their death (Taylor, 
Ostermann, Van Houtven, Tulsky & Steinhauser, 
2007). 
Similar to hospice care, is the option for private 
in-home care, which enables a patient and their 
families more control in what type of care is 
provided.  Many commercial insurance plans, as well 
as Medicare, offer an in-home care benefit, allowing 
various healthcare providers to engage patients in the 
comfort of their own homes at end-of-life (ACHC; 
Maxim Healthcare Services, 2009). In-home care can 
include around-the-clock nursing, nursing aide, or 
physical therapy care, resulting in considerable cost 
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savings when compared to hospital or institutional 
care. Skilled providers, such as registered nurses 
providing in-home care, are compensated at about 
$10 less per hour, than facility nurses. Similarly, 
unskilled providers, such as nursing aides or home 
health aides, are compensated at a rate of about $5 
less per hour than facility unskilled providers. For 
end-of-life patients serving out their final days, “there 




Pain management is a dicey subject for some 
healthcare professionals. It is fraught with moral and 
ethical concerns. There is not a “one size fits all” 
handbook for pain management medication at end-of-
life. Healthcare providers have to use sound 
judgment and education to determine the appropriate 
level of medication(s) to administer. A 
comprehensive pain assessment is required both to 
choose initial therapy and to measure its effectiveness 
(Abrahm, 1998). Generally, the severity of the 
patient’s symptoms will determine the amount of the 
drug given by the healthcare provider to the patient.  
The ethical concern from a provider standpoint arises 
most commonly when the patient is unable to 
verbally indicate their pain level, and the provider is 
forced to make a determination about appropriate 
types and amounts of medications. 
End-of-life can often be accompanied by severe 
pain and other unpleasant symptoms that cause undue 
suffering (ASPMN, 2003). Turning to pain 
management or palliative care techniques, can be a 
cost effective health option that may improve the 
quality of life (and the dying experience) for 
terminally ill individuals. Palliative care is defined by 
the World Health Organization as “improving the 
quality of life of patients and families who face life-
threatening illness, by providing pain and symptom 
relief, spiritual and psychosocial support to, from 
diagnosis to the end of life and bereavement (WHO-
Palliative Care, 2009).” Pain management procedures 
can be administered in an office setting, an outpatient 
ambulatory surgery facility, hospital, and/or in-home 
care. Regardless of the setting, however, healthcare 
providers often times have to walk a fine ethical line, 
between what is appropriate amount of medication 
for comfort, and what can be detrimental to the 
patient. 
For a patient that has mild pain and suffering, the 
provider may choose to give a lower strength 
medication such as an over-the-counter analgesic.  
However, if the patient’s pain goes into the moderate 
category, a controlled substance such as oxycodone 
may be given.  Severe pain levels for those suffering 
end-of-life illnesses are often treated by highly potent 
drugs, such as morphine, to allay pain symptoms.  
Drugs like morphine, if given in an accidentally 
overdosed quantity, can weaken a patient's pulse, 
shallow breathing, cause fainting, halt breathing, and 
can cause death at certain dosage levels (Morphine 
Information, 2009).  There can be a wide range from 
the initial dosage given to a patient, to the maximum 
recommended dose (Ortiz-Rios, 2009).   
Proportionate palliative sedation is the practice of 
administering the lowest dose of pain management 
therapy to achieve comfort for the patient.  
Proportionate palliative sedation is widely accepted 
as an ethical medical practice (Quill, 2009).  Contrast 
proportionate palliative sedation with palliative 
sedation to unconsciousness, a pain management 
therapy whereby unconsciousness is the intended 
effect to achieve maximum pain relief for the patient.  
The patient is then left in an unconscious state 
generally without artificial nutrition or hydration 
until the patient dies (Quill, 2009).  The practice has 
been condoned by the United States Supreme Court 
in Glucksberg, supra, wherein the Court held that 
“[a] patient who is suffering from a terminal illness 
and who is experiencing great pain has no legal 
barriers to obtaining medication from qualified 
physicians, even to the point of causing 
unconsciousness and hastening death”  However, the 
practice is considered controversial within the 
medical community and should not be used as a back 
door means of carrying out physician-assisted suicide 
(Quill, 2009). 
Whereas pain management may be controversial 
in nature, it is important to not overlook its important 
role in the end-of-life discussion.  When taking into 
account all the end-of-life aspects conferred herein, 
pain management can offer a sense of autonomy and 
comfort to a patient, while being a cost efficient 
health choice. With the extensive choices, both in 
treatment options and environments in which services 
can be rendered, pain management should be a 
meaningful option for anyone seeking or planning 
end-of-life care. 
       
Historical Policy Analysis – Lessons from the Past 
Healthcare policy reform recommendations, as 
previously mentioned and discussed, have largely 
been focused in three key areas with regard to end-of-
life: “(a) advance directives; (b) hospice benefit; and 
(c) pain management” (Werth & Blevens, 2002, p. 
406). 
Further to those recommendations, it is germane 
to examine outcomes of the PSDA to determine the 
extent to which legislative efforts can promote the 
use of advance directives. In a report completed 
nearly five years after the enactment of the PSDA, 
the General Accounting Office (GAO) indicated that 
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a significant majority of covered healthcare 
institutions were complying with most of the 
provisions of that legislation (GAO, 1995). The GAO 
report, however, expressed concern about the 
“effectiveness” of the legislation. Two of the major 
challenges to the efficacy of the PSDA identified in 
the aforementioned GOA report included: (1) the 
persistent low level of participation among people 
actually choosing to exercise the right to execute an 
advance directive and (2) the lack of thorough 
discussion between patient and healthcare provider 
regarding treatments that may be carried out pursuant 
to an advance directive for those individuals with 
completed advance directives (GAO, 1995).   
According to the GAO, a counseling session was 
deemed critical to ensure that the patient was fully 
aware of the implications of their decisions, as well 
as to ensure that the healthcare provider fully 
understood the patient’s wishes (GAO, 1995).  
According to several empirical studies, advance 
directive planning expectations have fallen short of 
the initial promise of the PSDA legislation 
(Prendergast, 2001). 
With respect to hospice services, the Tax Equity 
and Fiscal Responsibility Act of 1982 (42 U.S.C. § 
1395, et seq.), which expanded coverage for hospice 
care for qualified Medicare beneficiaries, was a 
significant legislative accomplishment (Blevins & 
Deason-Howell, 2002). However, making an accurate 
prognosis of the point in time that marks end-of-life 
(and, coincidentally, the start of Medicare benefits for 
hospice care) remains a substantial challenge (Werth 
& Blevens, 2002). Notwithstanding the significant 
advances in medicine, predicting death with a high 
degree of certainty remains extremely difficult 
(Scitovsky, 2005). As a result, there are wide 
variations in treatment periods, quality of care, and 
cost associated with hospice care on a patient-to-
patient basis. Improving our understanding of the 
causes of these variations could be enormously 
beneficial to benchmarking performance and 
standardizing best practices (White, Cochran, & 
Patel, 2002). 
Efforts to improve pain management at end-of-
life center primarily around three key issues: (1) 
managing the cost for effective pain management, 
which can be expensive and sometimes not covered 
by Medicare; (2) improving physician education 
about pain management; and, (3) dealing with 
regulatory barriers that may restrict a physician from 
prescribing certain aggressive pain management 
regimens (Werth & Blevens, 2002). Recent federal 
legislation initiatives related to end-of-life pain 
management have not seen much, if any, real success. 
The most recent, the Conquering Pain Act of 2005 
(S.B. 999), which proposed to establish “evidence-
based practice guidelines for pain treatment”, 
experienced a fate similar to its predecessors by 
failing to emerge from committee referral (S.B. 999). 
However, it has become more and more clear to the 
medical community that the importance of effective 
pain management during end-of-life cannot be 
understated. “To restore a balance between a 
physician's obligation to prolong life and obligation 
to relieve suffering, a peaceful death must be 
acknowledged as a legitimate goal of medicine and as 
an integral part of a physician's responsibilities” 
(Meier, Morrison, & Cassel, 1997, pg. 226).  
 
Imminent Crisis or Opportunity for Incremental 
Reform 
Whereas end-of-life concerns are certainly not 
confined to the elderly, it is important to note that 
approximately two-thirds of the people that die in the 
United States each year are the elderly, i.e., 65 or 
older (Scitovsky, 2005). This is significant because 
Medicare studies provide some of the best 
information on end-of-life costs (Scitovsky, 2005). 
Conceding the limitations of this data source, we can 
still glean valuable insights on end-of-life costs from 
its consideration. 
Approximately one-fourth of Medicare spending 
is attributable to individuals in their final year of life 
(Buntin & Huskamp, 2002). At least one study has 
reported that Medicare beneficiaries in their final 
year of life spend nearly six times as much as other 
Medicare beneficiaries (Hogan, Lunney, Gabel, & 
Lynn, 2001). Whereas on the surface this seems to 
suggest an imminent crisis with end-of-life costs, 
further research on the issue suggests otherwise. 
Of particular interest is the observation that the 
percentage of Medicare costs due to end-of-life care 
has remained relatively consistent over the last two 
decades (Hogan, et al., 2001). This same study 
concluded that end-of- life costs do not appear to be a 
leading cause of the growth in healthcare spending 
(Hogan, et al., 2001). In fact, the stability of this 
trend may suggest that higher end-of-life costs are 
largely inevitable and, consequently, there is little 
that can be effectively done to reduce the need for 
higher levels of end-of-life healthcare spending, 
particularly when related to acute care (Liu, Wiener, 
& Niefeld, 2006). Some researchers suggest that the 
higher cost of end-of-life care may be primarily 
associated with treating severe illness and functional 
impairment, rather than exceptional or extraordinary 
circumstances associated with being near the end-of-
life (Hogan, et al., 2001). Further to this hypothesis, 
multiple studies have concluded that the healthcare 
costs of decedents and survivors suffering from 
similar illnesses are comparable (Liu, et al., 2006).  
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These studies suggest that seeking ways to reduce 
end-of-life healthcare costs, while highly worthy of 
consideration, may not be the panacea that some 
reform advocates suggest to controlling the high 
growth of national healthcare spending. With respect 
to end-of-life care, there are certainly many prospects 
for incremental reform. Some of these opportunities 
will be explored below. Maintaining reform 
expectations within the realm of actionable and 
realistic is imperative. As Scitovksy (2005) 
concludes, “the data from studies conducted to date 
do not provide a basis for a policy of singling out one 
group of patients for cost-containment strategies” (p. 
837). 
Perception vs. Reality 
The ensuing controversy associated with the end-
of-life counseling provision in H.R. 3200 § 1233 
prompts us to consider additional questions. What do 
we really know about cost inefficiencies that exist 
with respect to end-of-life care or the quality of end-
of-life care?  Can we significantly reduce healthcare 
spending by reducing end-of-life healthcare costs 
without sacrificing quality of care? A common 
perception is that there are widespread cost 
inefficiencies and unnecessary provisions of 
healthcare during the end-of-life. While it is clear that 
inefficiencies do exist, the potential cost savings from 
end-of-life care reforms are not as certain. A recently 
completed study by the Urban Institute, a public 
policy research organization, indicated that while 
there were opportunities for cost savings, most of 
healthcare spending at the end-of-life was 
unavoidable (Urban Institute, 2009). This same report 
suggested that many analyses that target the “high 
cost of dying” inappropriately disregard similarly 
sick survivors that receive comparable care and 
benefited from the high cost treatments (Urban 
Institute, 2009). 
In a 2009 report,  “How Can We Pay for 
Healthcare Reform,” the Urban Institute identified 
over $1.3 trillion in possible cost savings over a ten 
year period. Of this amount, the cost savings 
attributable to end-of-life healthcare reform was 
about $91 billion over the ten-year period from 2010-
2019 (Urban Institute, 2009). Clearly, this estimated 
level of potential healthcare savings is not trivial. 
Yet, it accounts for only approximately seven percent 
(7%) of the total estimated cost savings identified in 
the report. Most of the end-of-life cost savings 
estimate in the Urban Institute’s 2009 study was 
attributable to reducing Medicare beneficiary related 
costs by 1.25% per year (Urban Institute, 2009). 
Accordingly, while the potential for end-of-life 
related cost savings does exist, it is prudent to 
moderate expectations with respect to the attainable 
impact that may have on healthcare reform. 
What can we state about the potential for 
improving the quality of end-of-life care? The 
common perception and, in some respects, common 
fear, regarding this issue may be that greater 
consideration of palliative care will likely involve 
decisions leading to less quality of care. While the 
results of much of the earlier qualitative research 
were mixed, relatively recent quantitative research 
appears to indicate that palliative care particularly 
when it is possible to provide at home provided the 
highest quality of care satisfaction from the 
perspective of family members (Teno, Clarridge, 
Casey, et al., 2004; Higginson, Finlay, Goodwin, et 
al., 2003). Notwithstanding the recent research, the 
possible benefits of palliative care are not fully 
understood. Unfortunately, many still fear that 
palliative care means the end of care.  
 
Actionable Initiatives 
What can be done to improve the provision of 
end-of-life care? Is it realistic to expect quality 
improvements while pursuing cost efficiencies? 
Discussed below are key initiatives that individuals, 
healthcare providers, and the government may 
consider to potentially improve end-of-life care.  
Individual Action 
As individuals, and as a society, we would 
benefit by becoming more comfortable with death. 
This seems too obvious to even mention. Death is a 
certainty for all of us. However, for too many of us, 
death is still a subject we avoid discussing even with 
our closest loved ones. It is difficult, if not 
impossible, to be adequately prepared for death if we 
are reluctant to discuss it. If, as individuals, we seek 
autonomy over our healthcare decisions, we must be 
prepared to accept responsibility for the directives we 
make in connection therewith. 
Advance directives are often promoted as a 
means for achieving patient autonomy (Kass-
Bartelmes, Hughes, & Rutherford, 2003). Yet, 
research indicates that patients (and/or their 
appointed healthcare surrogates) are not following 
through with the directives contained therein. A 
recent research study indicates that advance 
directives are actually completed and signed by less 
than 25% of most patient groups (Perkins, 2007). 
Some of the reasons cited for not completing advance 
directives were avoiding death related discussions, 
lack of awareness, lack of understanding, and poor 
support from healthcare personnel requesting 
completion of the forms (Perkins, 2007). 
It is important to note that, given the low 
completion rates and other implementation 
limitations, there remains considerable room for 
improvement of the advance directive (Perkins, 
2007). For example, one advance directive 
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“implementation problem is poor proxy 
representation” (Perkins, 2007, p. 53). The lack of 
unambiguous, regular, or recent instructions between 
the patient and proxy (i.e., family member or 
designated significant other) may result in 
overwhelming emotional anxiety and flawed 
decision-making by the proxy (Perkins, 2007, p. 53). 
This underscores the importance of family members 
or significant others to reach out and initiate the end-
of-life discussion if it has not been initiated by the 
patient. 
Notwithstanding these limitations related to 
advance directives process must be emphasized over 
outcome. The process of discussing a patient’s 
wishes and their options with a healthcare provider, 
as well as their family, at early and regular intervals 
can be immensely valuable in reducing potential 
uncertainties among family members and healthcare 
providers and, consequently, more closely aligning 
end-of-life care decisions with a patient’s true 
intentions.  
Healthcare Provider Action 
With respect to healthcare providers, two 
potential areas for consideration arise: (1) improving 
communication between the healthcare provider and 
patient; and, (2) improving the delivery of palliative-
oriented care. 
Effective communication requires active 
involvement by all relevant participants. Whereas we 
have noted the value of a patient being willing to 
discuss end-of-life matters with their healthcare 
providers, it is of equal, if not greater importance, for 
the healthcare provider to be a good listener and 
advisor in this communication process.  In evaluating 
“what matters most” to patients during their end-of-
life care, “having trust and confidence” in their 
doctors was “most frequently rated as extremely 
important” in a recently completed study of seriously 
ill patients (Heyland, Dodek, Rocker, et al., 2006, p. 
635). 
Research suggests that a patient’s “trust and 
satisfaction” levels may be dependent on their doctor 
developing “relational closeness” with the patient 
(Breen, Wan, Zhang, et al., 2008, p.159). To support 
the healthcare provider in fostering this closer 
relationship, addressing the nature of patient centered 
dimensions of care may be helpful. As described by 
the Picker Institute, based on more than 350,000 
patient survey interviews, patient-centered 
dimensions of care include the following: “(1) respect 
for the patient’s values, preferences, and expressed 
needs; (2) access to care; (3) information and 
education; (4) emotional support to relieve fear and 
anxiety; (5) involvement of family and friends; (6) 
continuity and secure transition between healthcare 
settings; (7) physical comfort; and (8) coordination 
and integration of care” (Breen, Wan, Zhang, et al., 
2008, p. 156).  The same study noted that almost four 
of five physicians could potentially improve their 
delivery of care by more effectively adopting 
“patient-centric” dimensions of care (Breen, Wan, 
Zhang, et al., 2008, p. 156). Another recent 
quantitative study also found that “increasing 
communication between patients and their physicians 
is associated with better outcomes and with less 
expensive medical care” (Zhang, Wright, Huskamp, 
et al., 2009, p. 487). 
Another area that warrants further consideration 
among healthcare providers is palliative care. There 
is an increasing amount of research based on the 
perspective of patients and family members that 
indicates a potential to improve the quality of the 
end-of-life experience by greater consideration of 
multi-disciplinary palliative care (Teno, et al., 2004; 
Mitchell, 2002; Byock, Twohig, Merriman, et al., 
2006). Research also shows that the improved quality 
of care can also be more cost effective (Byock, et al., 
2006). An Archives of Internal Medicine study 
observed that when advanced cancer patients had 
candid end-of-life discussions with their doctors they 
experienced a reduction in acute care services and 
there was an observed negative association between 
quality of care and costs in the last week of life 
(Zhang, et al., 2009). 
“An expansion of palliative care programs in 
hospitals” was one of the key policy 
recommendations of a recent study that could 
potentially result in lower healthcare costs while 
concurrently improving the quality of end-of-life care 
(Zhang, et al., 2009, p. 488). Whereas significant 
progress has been made in the acceptance and 
delivery of palliative care, the opportunity for 
additional improvement remains significant, 
particularly in the areas of healthcare provider and 
patient education, properly recognizing and 
discussing the futility of care, and in the delivery of 
coordinated palliative care in a multi-disciplinary 
manner (Chwang, 2009; Meier, Morrison, & Cassel, 
1997; Mahmood-Yousuf, Munday, King, et al., 
2008).  
Government Action 
Research suggests that a significant role exists 
for government in improving end-of-life healthcare. 
Effective policies and reform initiatives require an in-
depth understanding of current outcomes and costs. 
There is a need to gather better healthcare utilization 
and cost data on the experiences of end-of-life 
patients (Wiener & Tilly, 2003). Improving 
information technology within the healthcare system 
offers the one potential means whereby to improve 
quality of care, efficiency, and lower costs (Chugh, 
2009). 
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Whereas many advocate the expansion of the 
Medicare hospice benefit and greater use of palliative 
care services, additional evaluation may be needed on 
quality of life indicators as well as the cost 
effectiveness of palliative or hospice care. While 
improving accessibility to palliative services 
unequivocally provides greater choice and autonomy 
for the patient, the cost effectiveness of such 
programs remains unclear. Some studies, as stated 
earlier, report significantly lower costs for patients 
receiving palliative care while other studies have 
concluded that the comparative costs for hospice 
service were only marginally lower for cancer 
patients and higher for non-cancer patients 
(Campbell, Lynn, Louis, et al., 2004). This same 
study concluded that “overall, hospice users incur an 
estimated 4% greater [Medicare] costs than do 
similar patients who do not use hospice” (Campbell, 
Lynn, Louis, et al., 2004, p. 275). With respect to 
addressing the final wishes of the patient, a recent 
quality in end-of-life care study revealed that dying at 
home was not as important to patients as not being a 
burden to family (Heyland, Dodek, Rocker, et al., 
2006). Government can assume a significant role in 
sponsoring greater research that is needed to better 
understand patient and family preferences, quality 
indicators of end-of-life care, and the relative cost 
effectiveness of palliative care versus traditional 
hospital services. 
Another area that needs greater public policy 
attention is expanding access to more effective pain 
management. Research indicates that inadequate pain 
management remains a significant problem during 
end-of-life care (Imahof & Kaskie, 2008). A recent 
study concluded that both federal and state polices 
should be improved with respect to promoting more 
effective pain management during end-of-life 
(Imahof & Kaskie, 2008). Policy oriented pain 
management studies indicate that the greatest 
promise for effective policy reform in pain 
management are likely to begin with initiatives at the 
state level through the work of state attorney generals 
and state medical boards (Imahof & Kaskie, 2008; 
Edmondson, 2006). State attorneys general, in 
particular, may be in the best position to improve 
collaboration between “law enforcement and the 
medical community about the balance between 
effective pain management and the battle against 
diversion of prescription drugs” (Edmondson, 2006, 
p. 214). 
 
Conclusions and Recommendations 
Policy reform expectations for end-of-life care 
stemming from reform of the American healthcare 
system should be significantly moderated—there 
appears to be plenty of lower hanging fruit when it 
comes to systematic healthcare reform. While there 
may always be opportunities to improve the provision 
of end-of-life care, this remains an intensely personal 
issue. Many patients will experience a period of 
chronic illness before their death. Some dying 
patients may not lose hope until the very end, 
whereas others may accept their fate sooner. Patients 
deserve the autonomy to make these final end-of-life 
healthcare choices in their own right, in consultation 
with their families, and in consultation with their 
physicians. There is no “one-size fits all” end-of-life 
plan. Due to diverse medical and public opinions 
surrounding this issue, it is unlikely that public policy 
will be successful in finding a uniform, cost-efficient 
approach to end-of-life healthcare. This limited role 
for public policy suggests that healthcare providers 
and patients, in the first instance, must assume 
greater ownership and responsibility for end-of-life 
planning. As citizens, healthcare providers, family 
members, and future patients, we all should recognize 
that we have a responsibility to become more 
informed about end-of-life healthcare planning and to 
take the necessary steps to ensure that the final 
choices of patients are known and honored. 
Addressing this need to improve patient and 
healthcare provider awareness and accountability on 
this issue may be one of the areas where we may be 
best served in a non-intrusive, but supportive manner 
by public policy. The end-of-life planning provision 
in Section 1233 of H.R. 3200 may be a step in the 
right direction by providing education regarding 
advance directives and requiring periodic counseling 
and providing provider reimbursement for these 
services. It is unfortunate that the intention of the 
provision was not properly communicated in the 
midst of the heated debate surrounding healthcare 
reform. It is our hope that, in the event the measure 
does not mature into law, the issue be revisited again 
when calmer minds prevail. 
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